{"id":"W1993274621","doi":"10.1002/hep.26276","title":"Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial","year":2013,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatitis C virus research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"National Institute on Drug Abuse","keywords":"Ribavirin; Medicine; Gastroenterology; Internal medicine; Rash; Pegylated interferon; Adverse effect; Placebo; Hepatitis C virus; Dosing; Boceprevir; Pharmacology; Immunology; Virus; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001120276,0.001215244,0.001658095,0.0002147773,0.0004224009,0.0009423511,0.0007097929,0.001169692,0.00523669],"category_scores_gemma":[0.0007317826,0.0004509466,0.001028663,0.0002708707,0.0006669384,0.000623091,0.0002656071,0.002140705,0.0007887837],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005558197,"about_ca_system_score_gemma":0.0008314414,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008155684,"about_ca_topic_score_gemma":0.001952045,"domain_scores_codex":[0.9995645,0.0002441511,0.00002784805,0.0000585441,0.00003077896,0.00007419896],"domain_scores_gemma":[0.9995127,0.00008330923,0.0001079675,0.00002491233,0.00002873272,0.0002424597],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9419615,0.007977727,0.003886829,0.0006780078,0.0008436141,0.00008269939,0.00007995496,0.0004638035,0.003386975,0.0001057759,0.001259246,0.03927386],"study_design_scores_gemma":[0.8395748,0.145692,0.01076484,0.00008894812,0.0005732373,0.0001421161,0.0000471071,0.0006718425,0.0008202033,0.00009730118,0.001502198,0.00002539691],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905515,0.005962337,0.0001188513,0.0006546092,0.0002163579,0.0006768199,0.0004385019,0.0000515545,0.001329497],"genre_scores_gemma":[0.9928525,0.002628317,0.0004101307,0.000769298,0.0003790131,0.0006387154,0.0006826661,0.000007368404,0.001632072],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00523669,"threshold_uncertainty_score":0.01751846,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01591017208913845,"score_gpt":0.2674205272136614,"score_spread":0.251510355124523,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}